| Identification | Back Directory | [Name]
Butoxamin | [CAS]
2922-20-5 | [Synonyms]
D002078
Butoxamin
Butaxamina
Hydrochloride, butoxamine
2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol
Benzenemethanol, α-[1-[(1,1-dimethylethyl)amino]ethyl]-2,5-dimethoxy-
Benzenemethanol, alpha-(1-((1,1-dimethylethyl)amino)ethyl)-2,5-dimethoxy- | [Molecular Formula]
C15H25NO3 | [MDL Number]
MFCD00865513 | [MOL File]
2922-20-5.mol | [Molecular Weight]
267.36 |
| Hazard Information | Back Directory | [Uses]
Antidiabetic; antihyperlipoproteinemic. | [in vivo]
Butaxamine (0.1, 1, 10 mg/kg; p.o.; once daily for 12 weeks) increases bone mass indices and biomechanical parameters of strength and toughness in rats[1]. | Animal Model: | Seven-week-old male SHR/Izm and WKY/Izm rats[1] | | Dosage: | 0.1, 1, 10 mg/kg | | Administration: | P.o.; once daily for 12 weeks | | Result: | Prevented a decrease in bone mass and an increase in biomechanical fragility developing in SHR, suppressed both a decrease in bone formation and an increase in bone resorption in SHR. |
| [IC 50]
β2 adrenoceptor |
|
|